WO2012120365A1 - Stable pharmaceutical composition comprising ethinyl estradiol - Google Patents
Stable pharmaceutical composition comprising ethinyl estradiol Download PDFInfo
- Publication number
- WO2012120365A1 WO2012120365A1 PCT/IB2012/000432 IB2012000432W WO2012120365A1 WO 2012120365 A1 WO2012120365 A1 WO 2012120365A1 IB 2012000432 W IB2012000432 W IB 2012000432W WO 2012120365 A1 WO2012120365 A1 WO 2012120365A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethinyl estradiol
- sucrose
- pharmaceutically acceptable
- blend
- acceptable excipients
- Prior art date
Links
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 title claims abstract description 72
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960002568 ethinylestradiol Drugs 0.000 title claims abstract description 69
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000000583 progesterone congener Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 104
- 229930006000 Sucrose Natural products 0.000 claims description 61
- 239000005720 sucrose Substances 0.000 claims description 61
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 47
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 45
- 239000003826 tablet Substances 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 31
- 239000003381 stabilizer Substances 0.000 claims description 31
- 239000006185 dispersion Substances 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 29
- 229920002261 Corn starch Polymers 0.000 claims description 22
- 239000008120 corn starch Substances 0.000 claims description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 22
- 239000008101 lactose Substances 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 235000006708 antioxidants Nutrition 0.000 claims description 20
- 229940007690 drospirenone and ethinylestradiol Drugs 0.000 claims description 20
- -1 gallic acid ester Chemical class 0.000 claims description 20
- 239000004094 surface-active agent Substances 0.000 claims description 20
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 16
- 229960004845 drospirenone Drugs 0.000 claims description 16
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 16
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 239000000454 talc Substances 0.000 claims description 14
- 229910052623 talc Inorganic materials 0.000 claims description 14
- 235000012222 talc Nutrition 0.000 claims description 14
- 239000007891 compressed tablet Substances 0.000 claims description 13
- 229920000881 Modified starch Polymers 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 125000000185 sucrose group Chemical group 0.000 claims description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 229960000502 poloxamer Drugs 0.000 claims description 9
- 229920001983 poloxamer Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 7
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 229920003169 water-soluble polymer Polymers 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000000155 melt Substances 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 229920001531 copovidone Polymers 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- FVNKWWBXNSNIAR-BYPYZUCNSA-N (2s)-2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical class OC(=O)[C@@H](N)CC1=CNC(=S)N1 FVNKWWBXNSNIAR-BYPYZUCNSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- SKDGWNHUETZZCS-UHFFFAOYSA-N 2,3-ditert-butylphenol Chemical compound CC(C)(C)C1=CC=CC(O)=C1C(C)(C)C SKDGWNHUETZZCS-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000004982 aromatic amines Chemical class 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 239000000416 hydrocolloid Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229960004635 mesna Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 150000007965 phenolic acids Chemical class 0.000 claims description 2
- 235000009048 phenolic acids Nutrition 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 28
- 229960001375 lactose Drugs 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229920000858 Cyclodextrin Polymers 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000262 estrogen Substances 0.000 description 12
- 229940011871 estrogen Drugs 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 8
- 239000001116 FEMA 4028 Substances 0.000 description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 7
- 229960004853 betadex Drugs 0.000 description 7
- 230000001050 lubricating effect Effects 0.000 description 7
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920002675 Polyoxyl Polymers 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960004400 levonorgestrel Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000010525 oxidative degradation reaction Methods 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 2
- NAPPWIFDUAHTRY-XYDRQXHOSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 NAPPWIFDUAHTRY-XYDRQXHOSA-N 0.000 description 2
- QHTAUDUBRNENFJ-VCNAKFCDSA-N (8r,9s,13s,14s,17r)-17-ethynyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-6-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC(=O)C2=C1 QHTAUDUBRNENFJ-VCNAKFCDSA-N 0.000 description 2
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001688 coating polymer Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960004976 desogestrel Drugs 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- 229960001652 norethindrone acetate Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 229960000417 norgestimate Drugs 0.000 description 2
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229940038500 a synthetic conjugated estrogen Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229940006346 femhrt Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005638 polyethylene monopolymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Definitions
- the present invention relates to a stable pharmaceutical composition comprising ethinyl estradiol.
- the present invention also relates to a process for preparation of stable pharmaceutical composition comprising ethinyl estradiol.
- the present invention further relates to a stable pharmaceutical composition comprising ethinyl estradiol and progestogen.
- Ethinyl estradiol is a synthetic estrogenic compound, chemically known as 19-nor- 17a-pregnal,3,5(10)-triene-20-yne- 3, 17-diol.
- Ethinylestradiol is currently marketed in the United States in combination with desogestrel (Kariva ® , Desogen ® , Cyclessa ® , Mircette ® ); with drospirenone (Yasmin ® and Yaz ® ); with levonorgestrel (Seasonique ® , Loseasonique ® , Seasonale ® , Lybrel ® ); with norethindrone (Norinyl ® , Ovcon- 35 ® , Ovcon-50 ® ); with norethindrone acetate (Femhrt ® ) and with norgestimate (Ortho Tricyclen ® , Ortho Tricyclen Lo ® ).
- compositions contain natural or synthetic hormones in low dose, as the daily dose of these active ingredients is extremely low i.e. 0.1 ⁇ g - 500 ⁇ g, which lead to serious formulation challenges, such as to achieve formulation reproducibility and the homogenous distribution of the active ingredients.
- the stability of the active ingredients causes problems, which influences the shelf life of the composition, and this may be related to the low dose of the active ingredient and to the interaction with the different excipients. This is a crucial parameter in the case of estrogen, particularly the ethinylestradiol containing oral contraceptives. There are numbers of attempts to improve the stability of estrogen, especially ethinylestradiol containing pharmaceutical compositions
- US Patent No. 4, 1 15,563 relates to a solid pharmaceutical formulation comprising from 5 to 80 percent by weight of a pharmaceutically active steroid, 1 to 8 percent by weight of sodium starch glycolate and the remainder conventional excipients.
- US Patent No. 4, 154,820 relates to a stabilized therapeutic preparation exhibiting no oxidation and less than about 5% hydrolysis up to at least 24 months, consisting essentially of at least one alkali metal sulfate salt of a synthetic conjugated estrogen and an antioxidant, wherein the preparation is maintained at an alkalinity corresponding to a pH of not less than about 7.0.
- US Patent No. 4,380,534 relates to a solid pharmaceutical composition containing less than 5 mg/dosage unit of a powdered microdose drug subject to changes in crystal form stability selected from ethinyl estradiol, the improvement comprising said powdered microdose drug being coated with a hydrophobic wax.
- US Patent No. 4,383,992 relates to a water-soluble inclusion compound formed by complexing beta-cyclodextrin with a steroid compound having a molecular structure smaller than the inside dimension of the internal cavity of beta-cyclodextrin.
- US Patent No. 4,727,064 relates to a method of producing a stabilized amorphous complex of a drug and a mixture of cyclodextrin, which comprises the steps of dissolving an intrinsically amorphous mixture of cyclodextrin derivatives which are water soluble and capable of forming inclusion complexes with drugs in water and solubilizing lipophilic drugs into the aqueous media to form a solution and form a solublized drug/cyclodextrin complex.
- 4,877,774 relates a method for administering steroid hormones to patient needing supplemental steroid hormones by direct contact with mucosa or the conjunctiva comprising contacting the mucosa of said patient with an effective amount of a steroid hormone complexed with crystalline gamma-cyclodextrin.
- US Patent No. 5,376,641 relates to water soluble compound formed by complexing branched beta cyclodextrin with a steroid having a molecular structure that can fit into the cavity of the branched beta cyclodextrin and form a complex with the branched beta cyclodextrin.
- US Patent No. 5, 134, 127 relates to a pharmaceutically acceptable composition
- a pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a clathrate complex comprising a drug complexed to a cyclodextrin derivative a pharmaceutically acceptable cation; wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin.
- US Patent No. 5,382,434 relates to dry pharmaceutical preparations containing ultra-low doses of micronized steroidal medicinal agents in combination with a primary excipient having a high binding affinity and low demixing potential for the steroidal medicinal agent including spray-dried polyalcohols, granulated a-lactose monohydrate and mixtures thereof.
- the patent further discloses that the dry methods (dry-granulation and direct compression) are especially suitable for medicinal compounds which are sensitive to moisture or are unable to withstand the elevated drying temperatures associated with wet-granulation methods.
- US Patent No. 5,543, 157 relates to a pharmaceutical composition comprising an effective amount of active/cyclodextrin inclusion complex with pharmaceutical agent selected from the group consisting of estradiol; estriol; ethinylestradiol-3 -methyl ether; ethisterone; and mixtures thereof, said complex being prepared by the kneading method and having a particle size of less than about 5 microns which provides for fast release of said pharmaceutical agent.
- US Patent No. 5,547,948 relates a compressed tablet comprising a tablet core containing conjugated estrogens and a sugar coating in which said sugar coating incorporates a hormonal steroid and a release rate controlling amount of microcrystalline cellulose.
- US Patent No. 5,798,338 discloses a composition comprising an effective amount of 17a-ethinylestradiol, and an amount of a ⁇ -cyclodextrin in the form of clathrate, effective in reducing the oxidative degradation of the 17a- ethinylestradiol.
- the patent discloses the use of clathrate of ⁇ -cyclodextrin for prevention of the oxidative degradation reactions of the active ingredient.
- US Patent No. 5,928,668 relates to a method of dry blend compression of insoluble potent drug substances using a directly compressible, agglomerated excipient that is not a conventional spray dried polyalcohol or lactose.
- the patent further discloses that the estradiol and a number of other low-dose potent drugs precipitate in a variety of polymorphs and/or crystal habits on drying (during wet granulation process), which can affect the bioavailability of the drug.
- US Patent No. 5,976,570 relates to a method for preparing solid pharmaceutical dosage units containing low dose active ingredients using a wet granulation technique which employs aqueous solvents and surfactants.
- US Patent No. 6, 156,341 relates to pharmaceutical agents that contain gallic acid ester as an antioxidant in combination with a steroidal active ingredient.
- US Patent No. 6,958,326 relates to a pharmaceutical a composition comprising a granulated preparation comprising a complex between an estrogen and a cyclodextrin, the composition having a stability such that said estrogen is in an amount of at least 90% w/w in relation to the initial content of said estrogen after storage for 12 months at 40° C and 75% relative humidity (RH); and the composition being essentially free of polyvinylpyrrolidone.
- US Patent Nos. 7,163,931 and 7,569,557 relates to a stable pharmaceutical product comprising an estrogen, comprising complexed estrogens or sensitive complexes between a cyclodextrin and an estrogen. The patent further discloses that the degradation of estrogens, such as ethinyl estradiol, in conventional products, is one of the most critical issues with regard to product shelf life.
- US Publication No. 2005/0020554 relates to a method of preparing a pharmaceutical dosage form, the method comprising (a) encasing a pharmaceutical dosage form comprising an estrogen in a container essentially impervious to oxygen, and (b) purging the container with an inert gas, and pharmaceutical dosage forms made by the method thereof.
- compositions comprising an estrogen in combination with a progestin.
- the inventors of the present invention have developed a stable composition comprising ethinyl estradiol as active ingredient and sucrose as stabilizer which provides better or comparative, content uniformity, dissolution profile and/or bioavailability w.r.t commercialized dosage forms.
- the inventors have surprisingly found that the composition comprising ethinyl estradiol with sucrose as stabilizer is stable against thermal degradation, hydrolysis and oxidation of ethinyl estradiol.
- the main objective of present invention is to provide a stable pharmaceutical composition comprising ethinyl estradiol and one or more pharmaceutically acceptable excipients.
- Another objective of the present invention is to provide a process for the preparation of stable pharmaceutical composition comprising ethinyl estradiol having better or comparative dissolution properties, content uniformity and bioavailability w.r.t. commercially available dosage form.
- the present invention provides a stable pharmaceutical composition
- a stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
- the present invention also provides a stable premix composition
- a stable premix composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
- the present invention provides a stable pharmaceutical composition
- a stable pharmaceutical composition comprising ethinyl estradiol, progestogen, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
- one or more pharmaceutically acceptable excipients are selected from diluent, binder, disintegrant, stabilizers, surfactant, antioxidants, water soluble polymers, glidant and lubricant.
- progestogen is selected from drosperinone, levonorgestrel, desogestrel, norethindrone, norethindrone acetate, norgestimate, norgestrel, cyproterone.
- the present invention provides a stable pharmaceutical composition
- a stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose or sucrose in mixture with other stabilizers.
- the present invention provides a stable pharmaceutical composition
- a stable pharmaceutical composition comprising ethinyl estradiol, drosperinone, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
- the amount of drospirenone used may be in the range from about 1 to about 5 mg and the amount of ethinyl estradiol used may be in the range from about 0.01 to about 0.05 mg.
- the stable pharmaceutical composition of the present invention is substantially free of surfactant.
- the present invention further relates to a stable pharmaceutical composition
- a stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer, an antioxidant, a surfactant and optionally one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
- Ethinyl estradiol shows thermal degradation followed by hydrolysis and very much prone to oxidation also.
- the formulation of ethinyl estradiol with sucrose results in stable formulation.
- ⁇ Sucrose is classified as a non-reducing sugar and doesn't get oxidized by mild oxidizing agent.
- Sucrose has a water activity of ⁇ 0.8 which discourage the kinetic rates of many reaction.
- Sucrose has high value of osmotic pressure which helps the carrier mediated transport of molecules across the cell membrane resulting in increased absorption.
- the present invention further relates to a stable pharmaceutical composition
- a stable pharmaceutical composition comprising ethinyl estradiol, progestogen, a stabilizer, a water soluble polymer, an antioxidant, a surfactant and optionally one or more pharmaceutically acceptable excipients.
- Suitable binders used according to the present invention are selected from the group comprising sucrose, cellulose and its derivatives including, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose and hydroxyethyl cellulose, carboxymethyl cellulose; starch and its derivatives; hydrocolloids; sugars; polyvinyl pyrrolidone, copovidone, methacrylic acid copolymers and the like or combination thereof.
- the amount of binder may range from about 1-40%, preferably 1 -20% by weight of the dosage form.
- Suitable diluents used according to the present invention are selected from sugars such as lactose, sucrose, dextrose; sugar alcohols such as mannitol, sorbitol, xylitol, lactitol; Starlac® (co-processed mixture of Starch and lactose), Microcelac® (co-processed mixture of microcrystalline cellulose and lactose), starch, corn starch, modified starches, pregelatinized starch, dibasic calcium phosphate, tribasic calcium phosphate, powdered cellulose, microcrystalline cellulose, silicified microcrystalline cellulose and the like or combinations thereof.
- the amount of diluent may range from about 5-95%, preferably 10- 70% by weight of the dosage form.
- Suitable disintegrants used according to the present invention are selected from low-substituted hydroxypropyl cellulose; cross-linked polyvinylpyrrolidone; cross-linked sodium carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose; sodium starch glycolate; pregelatinized starch and the like or combinations thereof.
- the amount of disintegrant may range from about 1-30%, preferably 1-20% by weight of the dosage form.
- Suitable lubricants used according to the present invention are selected from calcium stearate, glycerol behenate, magnesium stearate, mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, vegetable oil, zinc stearate and the like or combinations thereof.
- the amount of lubricant may range from about 0.01-5%, preferably 0.1-2% by weight of the dosage form.
- Suitable glidants of the present invention include calcium silicate, magnesium carbonate, magnesium oxide, magnesium silicate, talc, colloidal silicon dioxide, starch and the like.
- the glidant may be used in the range of 0.01 -5%, preferably 0.1-2% by weight of the dosage form.
- Surfactants are compounds which are capable of improving the wetting of the drug and/or enhancing the dissolution.
- the surfactants can be selected from hydrophilic surfactants or lipophilic surfactants or mixtures thereof.
- the surfactants can be anionic, nonionic, cationic, and zwitterionic surfactants.
- Surfactants according to the present invention include, but not limited to, polyoxyethylene alkylaryl ethers such as polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether; polyethylene glycol fatty acid esters such as PEG monolaurate, PEG dilaurate, Polyethylene glycol 660 12- hydroxyl Stearate Ph.Eur.
- Polyoxyl 15 hydroxystearate NF (Solutol HS 15), PEG distearate, PEG dioleate; polyoxyethylene sorbitan fatty acid ester such as polysorbate 40, polysorbate 60, polysorbate 80; sorbitan fatty acid mono esters such as sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, polyoxyethylene castor oil derivates such as polyoxyl castor oil, polyoxyl hydrogenated castor oil, sodium lauryl sulphate, monooleate, monolaurate, monopalmitate, monostearate, sodium dioctyl sulfosuccinate (DOSS), lecithin, stearylic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, cremophore RH 40, and the like or combinations thereof.
- the surfactant
- Antioxidants prevent the oxidative degradation of substance.
- Exemplary anti-oxidants include, but not limited to, ascorbic acid and its salts and derivatives, vitamin E, vitamin E acetate, tocopherols and their derivatives, citric acid, gallic acid ester, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), di-tert-butylphenol, tertiary butylhydroquinone, aromatic amines, phenolic acids, enzymatic antioxidants, flavonoids, N- acetylcysteine, mesna, glutathione, thiohistidine derivatives, triazoles; tannins, cinnamic acid, hydroxycihnamatic acids and their esters, their mixtures and the like or combinations thereof.
- the antioxidant may be used in the range of 0.001-5% by weight of the dosage form.
- Stabilizers used according to the present invention include sucrose, sucrose fatty acid esters, polyethylene glycol, polyvinyl alcohol, xanthan gum, maltodextrin, EDTA, poloxamer, trehalose and the like or combinations thereof.
- Water soluble polymers according to the present invention include, but not limited to, polyethylene glycol, homopolymers and copolymers of N-vinyl lactams, especially homopolymers and copolymers of N-vinyl pyrrolidone, e.g. polyvinylpyrrolidone, copolymers of N-vinyl pyrrolidone and vinyl acetate e.g. copovidone, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene oxide, polyacrylates, methacrylate copolymers, methyl methacrylate, butyl methacrylate and the like or combinations thereof.
- the water soluble polymer may be used in the range of about 0.01 to 10% by weight of the dosage form.
- the pharmaceutical composition according to the present invention may be prepared by any method known in the art such as melt extrusion, solid dispersion, solid solution, coprecipitation, wet granulation, melt granulation, dry granulation and/or direct compression.
- the present invention provides a stable pharmaceutical composition comprising:
- diluents selected from lactose, sucrose, corn starch and microcrystalline cellulose or mixtures thereof,
- c) stabilizer selected from sucrose, sucrose fatty acid esters or mixtures thereof,
- water soluble polymer selected from polyethylene, glycol, methacrylate copolymers and copovidone or mixtures thereof
- antioxidant selected from vitamin E, vitamin E acetate, butylated hydroxyanisole and butylated hydroxytoluene
- surfactant selected from poloxamer, sodium lauryl sulfate and polysorbate or mixtures thereof.
- the present invention also provides a stable pharmaceutical composition comprising:
- diluents selected from lactose, sucrose, corn starch and microcrystalline cellulose or mixtures thereof,
- c) stabilizer selected from sucrose, sucrose fatty acid esters or mixtures thereof,
- disintegrant selected from corn starch, pregelatinized starch and croscarmellose sodium, surfactant selected from poloxamer, sodium lauryl sulphate and polysorbate,
- antioxidant selected from vitamin E, vitamin E acetate, butylated hydroxyanisole and butylated hydroxytoluene,
- surfactant selected from poloxamer, sodium lauryl sulfate and polysorbate or mixtures thereof,
- lubricant selected from magnesium stearate, sodium stearyl fumarate and stearic acid, and
- glidant selected from talc, colloidal silicon dioxide.
- a stable pharmaceutical composition comprising ethinyl estradiol prepared by a process comprising the steps of: a) blending ethinyl estradiol and sucrose along with one or more pharmaceutically acceptable excipients,
- step (b) melting the blend of step (a) at 40-50°C with mixing till it liquefies in jacketed vessel
- step (c) mixing the melt of step (b) with one or more pharmaceutically acceptable excipients, and d) cooling the blend of step (c) to room temperature and sifting the cooled blend.
- a stable premix composition comprising ethinyl estradiol prepared by the process comprising the steps of: a) blending ethinyl estradiol and sucrose along with one or more pharmaceutically acceptable excipients,
- step (b) melting the blend of step (a) at 40-50°C with mixing till it liquefies in jacketed vessel
- step (b) mixing the melt of step (b) with one or more pharmaceutically acceptable excipients
- step (c) cooling the blend of step (c) to room temperature and sifting the cooled blend.
- the present invention further provides a stable pharmaceutical composition comprising progestogen and ethinyl estradiol prepared by the process comprising the steps of:
- step (a) blending/lubricating the blend of step (a) with one or more extragranular pharmaceutically acceptable excipients
- step (b) compressing the blend of step (b) into tablets or filling into capsules.
- the present invention further provides a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- step (b) granulating the blend of step (a) with sucrose solution or dispersion and drying the wet granules
- the present invention further provides a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- step (a) granulating the blend of step (a) with solution/dispersion of step (b) and drying the wet granules
- the present invention further provides a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- step (a) granulating the blend of step (a) with solution/dispersion of step (b) and drying the wet granules
- the present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- step (a) granulating the blend of step (a) with solution/dispersion of step (b) and drying the wet granules
- the present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- step (a) granulating half the blend of step (a) with solution/dispersion of step (b) and drying the wet granules
- step (e) granulating the remaining half of the blend of step (a) with solution/dispersion of step (d) and drying the wet granules
- step (c) blending/lubricating the granules of step (c) and step (e) with one or more extragranular pharmaceutically acceptable excipients, and g) compressing the granules into tablets or filling into capsules.
- the present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- step (b) preparing solution/dispersion of drospirenone, ethinyl estradiol and an antioxidant in a suitable solvent, c) preparing solution/dispersion of sucrose in a suitable solvent and mixing with the solution/dispersion of step (b),
- step (a) granulating the blend of step (a) with solution/dispersion of step (c) and drying the wet granules
- the present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
- sucrose a) blending sucrose along with one or more pharmaceutically acceptable excipients
- step (b) preparing solution/dispersion of sucrose in a suitable solvent and mixing with the solution/dispersion of step (b),
- step (a) granulating the blend of step (a) with solution/dispersion of step (c) and drying the wet granules
- the solvents used for dispersion /solution may be selected from isopropyl alcohol, methanol, ethanol, water, acetone, methylene chloride and the like or mixtures thereof.
- Dispersion according to the present invention can be microdispersion or nanodispersion.
- the dispersion can be prepared and milled by any method known in the art.
- film coating composition comprises a solution / suspension of film coating polymers and one or more excipients such as such as plasticizers, opacifier, antisticking agent, colorants, sugars, pore forming agent, surfactants and the like.
- Suitable film coating polymers used according to the present invention are selected from ethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose and the like or mixtures thereof.
- Suitable anti-sticking agents used according to the present invention are selected from talc, magnesium stearate and the like or a mixture thereof.
- step (a) the blend of step (a) was melted at 40-50°C with mixing till it liquefies in jacketed vessel
- step (c) the blend of step (c) was cooled to room temperature and sifted.
- step (a) the blend of step (a) was lubricated with magnesium stearate
- step (b) the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
- Example 8 the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
- sucrose was dissolved in purified water and ethinyl estradiol was dispersed in the sucrose solution, ⁇
- step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
- step (d) the granules of step (c) were blended with remaining quantity of corn starch, talc and the blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
- step (e) the compressed tablets obtained in step (e) were coated with Opadry coating.
- sucrose was dissolved in purified water and drospirenone and ethinyl estradiol were dispersed in the sucrose solution,
- step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
- step (d) the granules of step (c) were blended with remaining quantity of corn starch, talc and the blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
- step (e) the compressed tablets obtained in step (e) were coated with Opadry coating.
- sucrose was dissolved in purified water and ethinyl estradiol and vitamin E were dispersed in the sucrose solution,
- step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
- step (d) the granules of step (c) were blended with remaining quantity of corn starch, talc and the blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
- step (e) the compressed tablets obtained in step (e) were coated with Opadry coating.
- sucrose was dissolved in purified water and mixed with the solution of step (b),
- step (a) was granulated using the dispersion of step (c) and the wet mass was dried, milled and sifted,
- step (d) the granules of step (d) were blended with remaining quantity of corn starch, talc and the final blend was lubricated with magnesium stearate, f) the lubricated blend of step (d) was compressed into tablets,
- step (e) the compressed tablets obtained in step (e) were coated with Opadry coating.
- vitamin E and poloxamer were dissolved in purified water and drospirenone, ethinyl estradiol were dispersed in the solution,
- step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
- step (d) the granules of step (d) were blended with remaining quantity of corn starch, talc and the final blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
- step (e) the compressed tablets obtained in step (e) were coated with Opadry coating.
- step (a) was granulated using the dispersion of step (c) and the wet mass was dried, milled and sifted,
- step (d) the granules of step (d) were blended with remaining quantity of lactose, remaining quantity of corn starch, talc and the final blend was lubricated with magnesium stearate,
- step (e) the lubricated blend of step (e) was compressed into tablets
- step (f) the compressed tablets obtained in step (f) were coated with Opadry coating.
- step (b) ethinyl estradiol and sucrose were taken in vessel, c) added purified water in step (b) and homogenized for 45-60 min using high speed homogenizer,
- step (a) was granulated using the dispersion of step (c) and the wet mass was dried, milled and sifted.
- step (a) the blend of step (a) was lubricated with magnesium stearate
- step (c) the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
- Drospirenone, ethinyl estradiol premix, lactose, corn starch and pregelatinized starch were sifted separately and blended,
- step (a) the blend of step (a) was lubricated with magnesium stearate
- step (c) the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
- Drospirenone, ethinyl estradiol, lactose, corn starch and pregelatinized starch were sifted separately and blended,
- step (a) the blend of step (a) was lubricated with magnesium stearate
- step (b) the lubricated blend of step (b) was compressed into tablets, and h) the compressed tablets obtained in step (c) were coated with Opadry coating.
- Stability Data Tablets prepared according to examples 15 and 17 were stored at 40°C/75% RH for six months and then tested by HPLC to determine the amount of impurities such as 6-keto ethinyl estradiol and related impurities.
- the stability data is given in table 1.
- Stability Data Tablets prepared according to examples 16 and 17 were stored at 50°C/75% RH for 5 days and then tested by HPLC to determine the amount of impurities such as 6-keto ethinyl estradiol and related impurities.
- the stability data is given in table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The technical field of the present invention relates to a stable pharmaceutical composition comprising ethinyl estradiol. The present invention also relates to a process for preparation of a stable pharmaceutical composition comprising ethinyl estradiol. The present invention further relates to a stable pharmaceutical composition comprising ethinyl estradiol and progestogen.
Description
STABLE PHARMACEUTICAL COMPOSITION COMPRISING
ETHINYL ESTRADIOL
Field of the invention
The present invention relates to a stable pharmaceutical composition comprising ethinyl estradiol. The present invention also relates to a process for preparation of stable pharmaceutical composition comprising ethinyl estradiol. The present invention further relates to a stable pharmaceutical composition comprising ethinyl estradiol and progestogen.
Background of the invention ¾ Oral contraceptives including the combination of gestagen and estrogen components are used for decades. Ethinyl estradiol is a synthetic estrogenic compound, chemically known as 19-nor- 17a-pregnal,3,5(10)-triene-20-yne- 3, 17-diol.
Ethinylestradiol is currently marketed in the United States in combination with desogestrel (Kariva®, Desogen®, Cyclessa®, Mircette®); with drospirenone (Yasmin® and Yaz®); with levonorgestrel (Seasonique®, Loseasonique®, Seasonale®, Lybrel®); with norethindrone (Norinyl®, Ovcon- 35®, Ovcon-50®); with norethindrone acetate (Femhrt®) and with norgestimate (Ortho Tricyclen®, Ortho Tricyclen Lo®).
These pharmaceutical compositions contain natural or synthetic hormones in low dose, as the daily dose of these active ingredients is extremely low i.e. 0.1 μg - 500 μg, which lead to serious formulation challenges, such as to achieve formulation reproducibility and the homogenous distribution of the active ingredients. On the other hand, the stability of the active ingredients causes problems, which influences the shelf life of the composition, and this may be related to the low dose of the active ingredient and to the interaction with the different excipients. This is a crucial parameter in the case of estrogen, particularly the ethinylestradiol containing oral contraceptives. There are
numbers of attempts to improve the stability of estrogen, especially ethinylestradiol containing pharmaceutical compositions
Following are the references that disclose stable composition of ethinyl estradiol and its combination with progestogen.
US Patent No. 4, 1 15,563 relates to a solid pharmaceutical formulation comprising from 5 to 80 percent by weight of a pharmaceutically active steroid, 1 to 8 percent by weight of sodium starch glycolate and the remainder conventional excipients.
US Patent No. 4, 154,820 relates to a stabilized therapeutic preparation exhibiting no oxidation and less than about 5% hydrolysis up to at least 24 months, consisting essentially of at least one alkali metal sulfate salt of a synthetic conjugated estrogen and an antioxidant, wherein the preparation is maintained at an alkalinity corresponding to a pH of not less than about 7.0.
US Patent No. 4,380,534 relates to a solid pharmaceutical composition containing less than 5 mg/dosage unit of a powdered microdose drug subject to changes in crystal form stability selected from ethinyl estradiol, the improvement comprising said powdered microdose drug being coated with a hydrophobic wax.
US Patent No. 4,383,992 relates to a water-soluble inclusion compound formed by complexing beta-cyclodextrin with a steroid compound having a molecular structure smaller than the inside dimension of the internal cavity of beta-cyclodextrin.
US Patent No. 4,727,064 relates to a method of producing a stabilized amorphous complex of a drug and a mixture of cyclodextrin, which comprises the steps of dissolving an intrinsically amorphous mixture of cyclodextrin derivatives which are water soluble and capable of forming inclusion complexes with drugs in water and solubilizing lipophilic drugs into the aqueous media to form a solution and form a solublized drug/cyclodextrin complex.
US Patent No. 4,877,774 relates a method for administering steroid hormones to patient needing supplemental steroid hormones by direct contact with mucosa or the conjunctiva comprising contacting the mucosa of said patient with an effective amount of a steroid hormone complexed with crystalline gamma-cyclodextrin.
US Patent No. 5,376,641 relates to water soluble compound formed by complexing branched beta cyclodextrin with a steroid having a molecular structure that can fit into the cavity of the branched beta cyclodextrin and form a complex with the branched beta cyclodextrin.
US Patent No. 5, 134, 127 relates to a pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a clathrate complex comprising a drug complexed to a cyclodextrin derivative a pharmaceutically acceptable cation; wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin.
US Patent No. 5,382,434 relates to dry pharmaceutical preparations containing ultra-low doses of micronized steroidal medicinal agents in combination with a primary excipient having a high binding affinity and low demixing potential for the steroidal medicinal agent including spray-dried polyalcohols, granulated a-lactose monohydrate and mixtures thereof. The patent further discloses that the dry methods (dry-granulation and direct compression) are especially suitable for medicinal compounds which are sensitive to moisture or are unable to withstand the elevated drying temperatures associated with wet-granulation methods.
US Patent No. 5,543, 157 relates to a pharmaceutical composition comprising an effective amount of active/cyclodextrin inclusion complex with pharmaceutical agent selected from the group consisting of estradiol; estriol; ethinylestradiol-3 -methyl ether; ethisterone; and mixtures thereof, said complex being prepared by the kneading method and having a particle size of less than about 5 microns which provides for fast release of said pharmaceutical agent.
US Patent No. 5,547,948 relates a compressed tablet comprising a tablet core containing conjugated estrogens and a sugar coating in which said sugar coating incorporates a hormonal steroid and a release rate controlling amount of microcrystalline cellulose.
US Patent No. 5,798,338 discloses a composition comprising an effective amount of 17a-ethinylestradiol, and an amount of a β-cyclodextrin in the form of clathrate, effective in reducing the oxidative degradation of the 17a- ethinylestradiol. The patent discloses the use of clathrate of β-cyclodextrin for prevention of the oxidative degradation reactions of the active ingredient.
US Patent No. 5,928,668 relates to a method of dry blend compression of insoluble potent drug substances using a directly compressible, agglomerated excipient that is not a conventional spray dried polyalcohol or lactose. The patent further discloses that the estradiol and a number of other low-dose potent drugs precipitate in a variety of polymorphs and/or crystal habits on drying (during wet granulation process), which can affect the bioavailability of the drug.
US Patent No. 5,976,570 relates to a method for preparing solid pharmaceutical dosage units containing low dose active ingredients using a wet granulation technique which employs aqueous solvents and surfactants.
US Patent No. 6, 156,341 relates to pharmaceutical agents that contain gallic acid ester as an antioxidant in combination with a steroidal active ingredient.
US Patent No. 6,958,326 relates to a pharmaceutical a composition comprising a granulated preparation comprising a complex between an estrogen and a cyclodextrin, the composition having a stability such that said estrogen is in an amount of at least 90% w/w in relation to the initial content of said estrogen after storage for 12 months at 40° C and 75% relative humidity (RH); and the composition being essentially free of polyvinylpyrrolidone.
US Patent Nos. 7,163,931 and 7,569,557 relates to a stable pharmaceutical product comprising an estrogen, comprising complexed estrogens or sensitive complexes between a cyclodextrin and an estrogen. The patent further discloses that the degradation of estrogens, such as ethinyl estradiol, in conventional products, is one of the most critical issues with regard to product shelf life.
US Publication No. 2005/0020554 relates to a method of preparing a pharmaceutical dosage form, the method comprising (a) encasing a pharmaceutical dosage form comprising an estrogen in a container essentially impervious to oxygen, and (b) purging the container with an inert gas, and pharmaceutical dosage forms made by the method thereof.
US Publication Nos. 2005/0207990, 2005/0220825, 2008/0175905 and 2009/01 17183 disclose compositions comprising an estrogen in combination with a progestin.
Despite the achieved results as disclosed in above prior art references there is a need for such products of estrogen-gestagen combinations, which possess enhanced stability, homogenous distribution, and are easy to manufacture.
The inventors of the present invention have developed a stable composition comprising ethinyl estradiol as active ingredient and sucrose as stabilizer which provides better or comparative, content uniformity, dissolution profile and/or bioavailability w.r.t commercialized dosage forms. The inventors have surprisingly found that the composition comprising ethinyl estradiol with sucrose as stabilizer is stable against thermal degradation, hydrolysis and oxidation of ethinyl estradiol.
Objective of the Invention
The main objective of present invention is to provide a stable pharmaceutical composition comprising ethinyl estradiol and one or more pharmaceutically acceptable excipients.
Another objective of the present invention is to provide a process for the preparation of stable pharmaceutical composition comprising ethinyl estradiol having better or comparative dissolution properties, content uniformity and bioavailability w.r.t. commercially available dosage form.
Summary of the Invention
Accordingly, the present invention provides a stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
In another embodiment, the present invention also provides a stable premix composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
In yet another embodiment, the present invention provides a stable pharmaceutical composition comprising ethinyl estradiol, progestogen, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
Detailed Description of the Invention
In another embodiment, one or more pharmaceutically acceptable excipients are selected from diluent, binder, disintegrant, stabilizers, surfactant, antioxidants, water soluble polymers, glidant and lubricant.
In another embodiment, progestogen is selected from drosperinone, levonorgestrel, desogestrel, norethindrone, norethindrone acetate, norgestimate, norgestrel, cyproterone.
In yet another embodiment, the present invention provides a stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose or sucrose in mixture with other stabilizers.
In yet another embodiment, the present invention provides a stable pharmaceutical composition comprising ethinyl estradiol, drosperinone, a
stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
In yet another embodiment, the amount of drospirenone used may be in the range from about 1 to about 5 mg and the amount of ethinyl estradiol used may be in the range from about 0.01 to about 0.05 mg.
The stable pharmaceutical composition of the present invention is substantially free of surfactant.
The present invention further relates to a stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer, an antioxidant, a surfactant and optionally one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
Ethinyl estradiol shows thermal degradation followed by hydrolysis and very much prone to oxidation also. The formulation of ethinyl estradiol with sucrose results in stable formulation.
· Sucrose is classified as a non-reducing sugar and doesn't get oxidized by mild oxidizing agent.
• Sucrose has a water activity of <0.8 which discourage the kinetic rates of many reaction.
• Sucrose when solubilized in water shows negative heat of enthalpy which works as a "coolant" preventing thermal degradation.
• Sucrose has high value of osmotic pressure which helps the carrier mediated transport of molecules across the cell membrane resulting in increased absorption.
The present invention further relates to a stable pharmaceutical composition comprising ethinyl estradiol, progestogen, a stabilizer, a water soluble polymer, an antioxidant, a surfactant and optionally one or more pharmaceutically acceptable excipients.
Suitable binders used according to the present invention are selected from the group comprising sucrose, cellulose and its derivatives including, ethyl
cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose and hydroxyethyl cellulose, carboxymethyl cellulose; starch and its derivatives; hydrocolloids; sugars; polyvinyl pyrrolidone, copovidone, methacrylic acid copolymers and the like or combination thereof. The amount of binder may range from about 1-40%, preferably 1 -20% by weight of the dosage form.
Suitable diluents used according to the present invention are selected from sugars such as lactose, sucrose, dextrose; sugar alcohols such as mannitol, sorbitol, xylitol, lactitol; Starlac® (co-processed mixture of Starch and lactose), Microcelac® (co-processed mixture of microcrystalline cellulose and lactose), starch, corn starch, modified starches, pregelatinized starch, dibasic calcium phosphate, tribasic calcium phosphate, powdered cellulose, microcrystalline cellulose, silicified microcrystalline cellulose and the like or combinations thereof. The amount of diluent may range from about 5-95%, preferably 10- 70% by weight of the dosage form.
Suitable disintegrants used according to the present invention are selected from low-substituted hydroxypropyl cellulose; cross-linked polyvinylpyrrolidone; cross-linked sodium carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose; sodium starch glycolate; pregelatinized starch and the like or combinations thereof. The amount of disintegrant may range from about 1-30%, preferably 1-20% by weight of the dosage form.
Suitable lubricants used according to the present invention are selected from calcium stearate, glycerol behenate, magnesium stearate, mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, vegetable oil, zinc stearate and the like or combinations thereof. The amount of lubricant may range from about 0.01-5%, preferably 0.1-2% by weight of the dosage form.
Suitable glidants of the present invention include calcium silicate, magnesium carbonate, magnesium oxide, magnesium silicate, talc, colloidal
silicon dioxide, starch and the like. The glidant may be used in the range of 0.01 -5%, preferably 0.1-2% by weight of the dosage form.
Surfactants are compounds which are capable of improving the wetting of the drug and/or enhancing the dissolution. The surfactants can be selected from hydrophilic surfactants or lipophilic surfactants or mixtures thereof. The surfactants can be anionic, nonionic, cationic, and zwitterionic surfactants. Surfactants according to the present invention include, but not limited to, polyoxyethylene alkylaryl ethers such as polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether; polyethylene glycol fatty acid esters such as PEG monolaurate, PEG dilaurate, Polyethylene glycol 660 12- hydroxyl Stearate Ph.Eur. or Polyoxyl 15 hydroxystearate NF (Solutol HS 15), PEG distearate, PEG dioleate; polyoxyethylene sorbitan fatty acid ester such as polysorbate 40, polysorbate 60, polysorbate 80; sorbitan fatty acid mono esters such as sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, polyoxyethylene castor oil derivates such as polyoxyl castor oil, polyoxyl hydrogenated castor oil, sodium lauryl sulphate, monooleate, monolaurate, monopalmitate, monostearate, sodium dioctyl sulfosuccinate (DOSS), lecithin, stearylic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, cremophore RH 40, and the like or combinations thereof. The surfactant may be used in the range of 0.001 -5% by weight of the dosage form.
Antioxidants prevent the oxidative degradation of substance. Exemplary anti-oxidants include, but not limited to, ascorbic acid and its salts and derivatives, vitamin E, vitamin E acetate, tocopherols and their derivatives, citric acid, gallic acid ester, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), di-tert-butylphenol, tertiary butylhydroquinone, aromatic amines, phenolic acids, enzymatic antioxidants, flavonoids, N- acetylcysteine, mesna, glutathione, thiohistidine derivatives, triazoles; tannins, cinnamic acid, hydroxycihnamatic acids and their esters, their mixtures and the
like or combinations thereof. The antioxidant may be used in the range of 0.001-5% by weight of the dosage form.
Stabilizers used according to the present invention include sucrose, sucrose fatty acid esters, polyethylene glycol, polyvinyl alcohol, xanthan gum, maltodextrin, EDTA, poloxamer, trehalose and the like or combinations thereof.
Water soluble polymers according to the present invention include, but not limited to, polyethylene glycol, homopolymers and copolymers of N-vinyl lactams, especially homopolymers and copolymers of N-vinyl pyrrolidone, e.g. polyvinylpyrrolidone, copolymers of N-vinyl pyrrolidone and vinyl acetate e.g. copovidone, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene oxide, polyacrylates, methacrylate copolymers, methyl methacrylate, butyl methacrylate and the like or combinations thereof. The water soluble polymer may be used in the range of about 0.01 to 10% by weight of the dosage form.
The pharmaceutical composition according to the present invention may be prepared by any method known in the art such as melt extrusion, solid dispersion, solid solution, coprecipitation, wet granulation, melt granulation, dry granulation and/or direct compression.
In another embodiment, the present invention provides a stable pharmaceutical composition comprising:
a) ethinyl estradiol,
b) diluents selected from lactose, sucrose, corn starch and microcrystalline cellulose or mixtures thereof,
c) stabilizer selected from sucrose, sucrose fatty acid esters or mixtures thereof,
d) water soluble polymer selected from polyethylene, glycol, methacrylate copolymers and copovidone or mixtures thereof,
e) antioxidant selected from vitamin E, vitamin E acetate, butylated hydroxyanisole and butylated hydroxytoluene,
f) surfactant selected from poloxamer, sodium lauryl sulfate and polysorbate or mixtures thereof.
In another embodiment, the present invention also provides a stable pharmaceutical composition comprising:
a) drospirenone and ethinyl estradiol as active ingredients,
b) diluents selected from lactose, sucrose, corn starch and microcrystalline cellulose or mixtures thereof,
c) stabilizer selected from sucrose, sucrose fatty acid esters or mixtures thereof,
d) disintegrant selected from corn starch, pregelatinized starch and croscarmellose sodium, surfactant selected from poloxamer, sodium lauryl sulphate and polysorbate,
e) antioxidant selected from vitamin E, vitamin E acetate, butylated hydroxyanisole and butylated hydroxytoluene,
f) surfactant selected from poloxamer, sodium lauryl sulfate and polysorbate or mixtures thereof,
g) lubricant selected from magnesium stearate, sodium stearyl fumarate and stearic acid, and
h) glidant selected from talc, colloidal silicon dioxide.
In a preferred embodiment, a stable pharmaceutical composition comprising ethinyl estradiol prepared by a process comprising the steps of: a) blending ethinyl estradiol and sucrose along with one or more pharmaceutically acceptable excipients,
b) melting the blend of step (a) at 40-50°C with mixing till it liquefies in jacketed vessel,
c) mixing the melt of step (b) with one or more pharmaceutically acceptable excipients, and
d) cooling the blend of step (c) to room temperature and sifting the cooled blend.
In another preferred embodiment, a stable premix composition comprising ethinyl estradiol prepared by the process comprising the steps of: a) blending ethinyl estradiol and sucrose along with one or more pharmaceutically acceptable excipients,
b) melting the blend of step (a) at 40-50°C with mixing till it liquefies in jacketed vessel,
c) mixing the melt of step (b) with one or more pharmaceutically acceptable excipients, and
d) cooling the blend of step (c) to room temperature and sifting the cooled blend.
The present invention further provides a stable pharmaceutical composition comprising progestogen and ethinyl estradiol prepared by the process comprising the steps of:
a) blending progestogen and ethinyl estradiol premix with one or more pharmaceutically acceptable excipients,
b) blending/lubricating the blend of step (a) with one or more extragranular pharmaceutically acceptable excipients, and
c) compressing the blend of step (b) into tablets or filling into capsules.
The present invention further provides a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending drospirenone, ethinyl estradiol along with one or more pharmaceutically acceptable excipients,
b) granulating the blend of step (a) with sucrose solution or dispersion and drying the wet granules,
c) compressing the granules into tablets or filling into capsules, and d) optionally film coating the compressed tablet.
The present invention further provides a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending drospirenone along with one or more pharmaceutically acceptable excipients,
b) preparing solution/dispersion of sucrose and ethinyl estradiol optionally antioxidant in a suitable solvent,
c) granulating the blend of step (a) with solution/dispersion of step (b) and drying the wet granules,
d) blending/lubricating the granules with one or more extragranular pharmaceutically acceptable excipients, and
e) compressing the granules into tablets or filling into capsules.
The present invention further provides a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending one or more pharmaceutically acceptable excipients,
b) preparing solution/dispersion of sucrose, drospirenone and ethinyl estradiol in a suitable solvent,
c) granulating the blend of step (a) with solution/dispersion of step (b) and drying the wet granules,
d) blending/lubricating the granules with one or more extragranular pharmaceutically acceptable excipients, and
e) compressing the granules into tablets or filling into capsules.
The present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending drospirenone along with one or more pharmaceutically acceptable excipients,
b) preparing solution/dispersion of sucrose, ethinyl estradiol and an antioxidant in a suitable solvent,
c) granulating the blend of step (a) with solution/dispersion of step (b) and drying the wet granules,
d) blending/lubricating the granules with one or more extragranular pharmaceutically acceptable excipients, and
e) compressing the granules into tablets or filling into capsules.
The present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending one or more pharmaceutically acceptable excipients,
b) preparing solution/dispersion of ethinyl estradiol and an antioxidant in a suitable solvent,
c) granulating half the blend of step (a) with solution/dispersion of step (b) and drying the wet granules,
d) preparing solution/dispersion of drospirenone and sucrose in a suitable solvent,
e) granulating the remaining half of the blend of step (a) with solution/dispersion of step (d) and drying the wet granules,
f) blending/lubricating the granules of step (c) and step (e) with one or more extragranular pharmaceutically acceptable excipients, and g) compressing the granules into tablets or filling into capsules.
The present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending one or more pharmaceutically acceptable excipients,
b) preparing solution/dispersion of drospirenone, ethinyl estradiol and an antioxidant in a suitable solvent,
c) preparing solution/dispersion of sucrose in a suitable solvent and mixing with the solution/dispersion of step (b),
d) granulating the blend of step (a) with solution/dispersion of step (c) and drying the wet granules,
e) blending/lubricating the granules with one or more extragranular pharmaceutically acceptable excipients, and
f) compressing the granules into tablets or filling into capsules.
The present invention further relates to a stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending sucrose along with one or more pharmaceutically acceptable excipients,
b) preparing solution/dispersion of drospirenone, ethinyl estradiol, surfactant and an antioxidant in a suitable solvent,
c) preparing solution/dispersion of sucrose in a suitable solvent and mixing with the solution/dispersion of step (b),
d) granulating the blend of step (a) with solution/dispersion of step (c) and drying the wet granules,
e) blending/lubricating the granules with one or more extragranular pharmaceutically acceptable excipients, and
f) compressing the granules into tablets or filling into capsules.
In an embodiment of the present invention, the solvents used for dispersion /solution may be selected from isopropyl alcohol, methanol, ethanol, water, acetone, methylene chloride and the like or mixtures thereof.
"Dispersion" according to the present invention can be microdispersion or nanodispersion. The dispersion can be prepared and milled by any method known in the art.
The solid dosage form of the present invention may be uncoated or or optionally coated.
In yet another embodiment of the present invention, film coating composition comprises a solution / suspension of film coating polymers and one or more excipients such as such as plasticizers, opacifier, antisticking agent, colorants, sugars, pore forming agent, surfactants and the like.
Suitable film coating polymers used according to the present invention are selected from ethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose and the like or mixtures thereof.
Suitable anti-sticking agents used according to the present invention are selected from talc, magnesium stearate and the like or a mixture thereof.
The following examples further exemplify the invention and are not intended to limit the scope of the invention. It is obvious to those skilled in the art to find out the composition for other dosage forms and substitute the equivalent excipients as described in this specification or with the one known to the industry.
Examples 1-6: Preparation of Ethinyl estradiol premix
a) ethinyl estradiol and sucrose were sifted separately and blended with one or more excipients from S. No. 3 to 7,
b) the blend of step (a) was melted at 40-50°C with mixing till it liquefies in jacketed vessel,
c) anhydrous lactose was mixed with the melt of step (b),
d) the blend of step (c) was cooled to room temperature and sifted. Example 7
The processing steps involved in manufacturing drospirenone and ethinyl estradiol tablets are given below:
a) drospirenone, ethinyl estradiol premix, lactose, pregelatinized starch ahd talc were sifted separately and blended,
b) the blend of step (a) was lubricated with magnesium stearate,
c) the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
Example 8
The processing steps involved in manufacturing drospirenone and ethinyl estradiol tablets are given below:
a) drospirenone, lactose monohydrate and half the quantity of corn starch were sifted separately and blended,
b) sucrose was dissolved in purified water and ethinyl estradiol was dispersed in the sucrose solution, ·
c) the blend of step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
d) the granules of step (c) were blended with remaining quantity of corn starch, talc and the blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
f) the compressed tablets obtained in step (e) were coated with Opadry coating.
Example 9
4 Lactose monohydrate 49.58
5 Corn Starch 15.00
6 Talc 2.00
7 Magnesium Stearate 0.40
8 Purified water q.s.
Coating
9 Opadry coating 4.00
Total weight of the tablet 84.00
The processing steps involved in manufacturing drospirenone and ethinyl estradiol tablets are given below:
a) lactose and half the quantity of corn starch were sifted separately and blended,
b) sucrose was dissolved in purified water and drospirenone and ethinyl estradiol were dispersed in the sucrose solution,
c) the blend of step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
d) the granules of step (c) were blended with remaining quantity of corn starch, talc and the blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
f) the compressed tablets obtained in step (e) were coated with Opadry coating.
Example 10
Coating
10 Opadry coating 4.00
Total weight of the tablet 84.00
The processing steps involved in manufacturing drospirenone and ethinyl estradiol tablets are given below:
a) drospirenone, lactose and half the quantity of corn starch were sifted separately and blended,
b) sucrose was dissolved in purified water and ethinyl estradiol and vitamin E were dispersed in the sucrose solution,
c) the blend of step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
d) the granules of step (c) were blended with remaining quantity of corn starch, talc and the blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
f) the compressed tablets obtained in step (e) were coated with Opadry coating.
Example 11
a) lactose and half the quantity of corn starch were sifted separately and blended,
b) drospirenone, ethinyl estradiol and vitamin E were dissolved in methanol,
c) sucrose was dissolved in purified water and mixed with the solution of step (b),
d) the blend of step (a) was granulated using the dispersion of step (c) and the wet mass was dried, milled and sifted,
e) the granules of step (d) were blended with remaining quantity of corn starch, talc and the final blend was lubricated with magnesium stearate, f) the lubricated blend of step (d) was compressed into tablets,
g) the compressed tablets obtained in step (e) were coated with Opadry coating.
Example 12
a) lactose, sucrose and half the quantity of corn starch were sifted separately and blended,
b) vitamin E and poloxamer were dissolved in purified water and drospirenone, ethinyl estradiol were dispersed in the solution,
c) the blend of step (a) was granulated using the dispersion of step (b) and the wet mass was dried, milled and sifted,
d) the granules of step (d) were blended with remaining quantity of corn starch, talc and the final blend was lubricated with magnesium stearate, e) the lubricated blend of step (d) was compressed into tablets,
f) the compressed tablets obtained in step (e) were coated with Opadry coating.
Example 13
The processing steps involved in manufacturing drospirenone and ethinyl estradiol tablets are given below:
a) part of lactose, half the quantity of sucrose and half the quantity of corn starch were sifted separately and blended,
b) vitamin E, poloxamer, drospirenone and ethinyl estradiol were dissolved in methanol,
c) remaining half of the quantity of sucrose was dissolved in purified water and mixed with the solution of step (b),
d) the blend of step (a) was granulated using the dispersion of step (c) and the wet mass was dried, milled and sifted,
e) the granules of step (d) were blended with remaining quantity of lactose, remaining quantity of corn starch, talc and the final blend was lubricated with magnesium stearate,
f) the lubricated blend of step (e) was compressed into tablets,
g) the compressed tablets obtained in step (f) were coated with Opadry coating.
Examples 14; Preparation of Ethinyl estradiol premix
The processing steps involved in manufacturing premix of ethinyl estradiol are given below:
a) lactose, sucrose and microcrystalline cellulose were sifted separately and blended,
b) ethinyl estradiol and sucrose were taken in vessel,
c) added purified water in step (b) and homogenized for 45-60 min using high speed homogenizer,
d) the blend of step (a) was granulated using the dispersion of step (c) and the wet mass was dried, milled and sifted.
Example 15
The processing steps involved in manufacturing ethinyl estradiol tablets are given below:
a) Ethinyl estradiol premix, lactose, pregelatinized starch and talc were sifted separately and blended,
b) the blend of step (a) was lubricated with magnesium stearate,
c) the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
Example 16
Coating
7 Opadry coating 4.000
8 Purified Water q.s.
Total weight of the tablet 84.000
The processing steps involved in manufacturing ethinyl estradiol tablets are given below:
a) Drospirenone, ethinyl estradiol premix, lactose, corn starch and pregelatinized starch were sifted separately and blended,
b) the blend of step (a) was lubricated with magnesium stearate,
c) the lubricated blend of step (b) was compressed into tablets, and d) the compressed tablets obtained in step (c) were coated with Opadry coating.
Example 17 -Comparative example without Sucrose
The processing steps involved in manufacturing ethinyl estradiol tablets are given below:
e) Drospirenone, ethinyl estradiol, lactose, corn starch and pregelatinized starch were sifted separately and blended,
f) the blend of step (a) was lubricated with magnesium stearate,
g) the lubricated blend of step (b) was compressed into tablets, and
h) the compressed tablets obtained in step (c) were coated with Opadry coating.
Stability Data: Tablets prepared according to examples 15 and 17 were stored at 40°C/75% RH for six months and then tested by HPLC to determine the amount of impurities such as 6-keto ethinyl estradiol and related impurities. The stability data is given in table 1.
Table 1
Table 2
Claims
1. A stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
2. A stable premix composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
3. A stable pharmaceutical composition comprising ethinyl estradiol, progestogen, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose.
4. The composition of claim 1, wherein one or more pharmaceutically acceptable excipients are selected from diluent, binder, disintegrant, stabilizers, surfactant, antioxidants, water soluble polymers, glidant and lubricant.
5. A stable pharmaceutical composition comprising ethinyl estradiol, a stabilizer and one or more pharmaceutically acceptable excipients, wherein stabilizer is sucrose or sucrose in mixture with other stabilizers.
6. The composition of claim 3, wherein the diluent is selected from lactose, sucrose, dextrose; sugar alcohols such as mannitol, sorbitol, xylitol, lactitol; Starlac® (co-processed mixture of Starch and lactose), Microcelac® (co- processed mixture of microcrystalline cellulose and lactose), starch, corn starch, modified starches, pregelatinized starch, dibasic calcium phosphate, tribasic calcium phosphate, powdered cellulose, microcrystalline cellulose, silicified microcrystalline cellulose or combination thereof.
7. The composition of claim 3, wherein the binder is selected from cellulose and its derivatives including, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose and hydroxyethyl cellulose, carboxymethyl cellulose; starch and its derivatives; hydrocolloids; sugars; polyvinyl pyrrolidone, copovidone, methacrylic acid copolymers or combination thereof.
8. The composition of claim 3, wherein the antioxidant is selected from ascorbic acid and its salts and derivatives, vitamin E, vitamin E acetate, tocopherols and their derivatives, citric acid, gallic acid ester, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), di-tert-butylphenol, tertiary butylhydroquinone, aromatic amines, phenolic acids, enzymatic antioxidants, flavonoids, N-acetylcysteine, mesna, glutathione, thiohistidine derivatives, triazoles; tannins, cinnamic acid, hydroxycinnamatic acids and their esters, their mixtures and the like or combinations thereof.
9. A stable pharmaceutical composition comprising:
a) drospirenone and ethinyl estradiol as active ingredients,
b) diluents selected from lactose, sucrose, corn starch and microcrystalline cellulose or mixtures thereof,
c) stabilizer selected from sucrose, sucrose fatty acid esters or mixtures thereof,
d) disintegrant selected from corn starch, pregelatinized starch and croscarmellose sodium, surfactant selected from poloxamer, sodium lauryl sulphate and polysorbate,
e) antioxidant selected from vitamin E, vitamin E acetate, butylated hydroxyanisole and butylated hydroxytoluene,
f) surfactant selected from poloxamer, sodium lauryl sulfate and polysorbate or mixtures thereof,
g) lubricant selected from magnesium stearate, sodium stearyl fumarate and stearic acid, and
h) glidant selected from talc, colloidal silicon dioxide.
10. A stable pharmaceutical composition comprising ethinyl estradiol prepared by a process comprising the steps of:
a) blending ethinyl estradiol and sucrose along with one or more pharmaceutically acceptable excipients, b) melting the blend of step (a) at 40-50°C with mixing till it liquefies in jacketed vessel,
c) mixing the melt of step (b) with one or more pharmaceutically acceptable excipients, and
d) cooling the blend of step (c) to room temperature and sifting the cooled blend.
1 1. A stable premix composition comprising ethinyl estradiol prepared by the process comprising the steps of:
a) blending ethinyl estradiol and sucrose along with one or more pharmaceutically acceptable excipients,
b) melting the blend of step (a) at 40-50°C with mixing till it liquefies in jacketed vessel,
c) mixing the melt of step (b) with one or more pharmaceutically acceptable excipients, and
d) cooling the blend of step (c) to room temperature ,and sifting the cooled blend.
12. A stable pharmaceutical composition comprising drospirenone and ethinyl estradiol prepared by the process comprising the steps of:
a) blending drospirenone, ethinyl estradiol along with one or more pharmaceutically acceptable excipients,
b) granulating the blend of step (a) with sucrose solution or dispersion and drying the wet granules,
c) compressing the granules into tablets or filling into capsules, and d) optionally film coating the compressed tablet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN667CH2011 | 2011-03-07 | ||
| IN667/CHE/2011 | 2011-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012120365A1 true WO2012120365A1 (en) | 2012-09-13 |
Family
ID=45976968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2012/000432 WO2012120365A1 (en) | 2011-03-07 | 2012-03-06 | Stable pharmaceutical composition comprising ethinyl estradiol |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012120365A1 (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN106692097A (en) * | 2015-07-16 | 2017-05-24 | 北京万生药业有限责任公司 | Reduced glutathione medicinal preparation |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| JP2020193229A (en) * | 2019-02-13 | 2020-12-03 | 富士製薬工業株式会社 | Oral solid composition, production method thereof, and oral tablet obtained by the production method |
| JP2022501472A (en) * | 2018-09-19 | 2022-01-06 | アイエスピー インヴェストメンツ エルエルシー | Peroxide-stable polymer composition, its manufacturing method, and its use |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN115813937A (en) * | 2022-12-01 | 2023-03-21 | 南通联亚药业股份有限公司 | A stable pharmaceutical composition containing drospirenone and estradiol and its preparation method |
Citations (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB760579A (en) * | 1952-09-18 | 1956-11-07 | George Reginald Costley | Improvements relating to percutaneous therapeutic preparations |
| GB888631A (en) * | 1959-02-24 | 1962-01-31 | Upjohn Co | Improvements in or relating to oral therapeutic compositions comprising steroids |
| GB1334813A (en) * | 1971-04-19 | 1973-10-24 | Richardson Merrell Inc | Contaception method and composition used therein |
| US4115563A (en) | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| US4154820A (en) | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| US4380534A (en) | 1980-04-07 | 1983-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Solid drug preparations |
| US4383992A (en) | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4877774A (en) | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| US5134127A (en) | 1990-01-23 | 1992-07-28 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5376641A (en) | 1988-08-15 | 1994-12-27 | American Maize Technology, Inc. | Method for making a steroid water soluble |
| US5382434A (en) | 1991-03-12 | 1995-01-17 | Akzo N.V. | Low steroid dose dry pharmaceutical preparation |
| US5543157A (en) | 1990-03-06 | 1996-08-06 | The Procter & Gamble Company | Solid consumer product compositions containing small particle clyclodextrin complexes |
| US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5798338A (en) | 1994-07-20 | 1998-08-25 | Schering Aktiengesellschaft | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
| US5928668A (en) | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
| US5976570A (en) | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
| DE19916383A1 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition with an extrusion |
| US6156341A (en) | 1994-07-04 | 2000-12-05 | Schering Aktiensgesellschaft | Low-dosed steroid tablets that contain gallic acid ester as an antioxidant, process for production, and use |
| US20050020554A1 (en) | 2003-06-06 | 2005-01-27 | Ahmed Salah U. | Stability of hormone formulations |
| US20050207990A1 (en) | 2004-03-10 | 2005-09-22 | Adrian Funke | Stabilised supersaturated solids of lipophilic drugs |
| US20050220825A1 (en) | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
| US6958326B2 (en) | 2000-12-20 | 2005-10-25 | Schering Ag | Cyclodextrin-drospirenone inclusion complexes |
| US20080175905A1 (en) | 2006-11-29 | 2008-07-24 | Wyeth | Estrogen/serm and estrogen/progestin bi-layer tablets |
| US20090117183A1 (en) | 2007-11-05 | 2009-05-07 | Sabine Fricke | Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same |
-
2012
- 2012-03-06 WO PCT/IB2012/000432 patent/WO2012120365A1/en active Application Filing
Patent Citations (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB760579A (en) * | 1952-09-18 | 1956-11-07 | George Reginald Costley | Improvements relating to percutaneous therapeutic preparations |
| GB888631A (en) * | 1959-02-24 | 1962-01-31 | Upjohn Co | Improvements in or relating to oral therapeutic compositions comprising steroids |
| GB1334813A (en) * | 1971-04-19 | 1973-10-24 | Richardson Merrell Inc | Contaception method and composition used therein |
| US4154820A (en) | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| US4115563A (en) | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| US4380534A (en) | 1980-04-07 | 1983-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Solid drug preparations |
| US4383992A (en) | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4877774A (en) | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| US5376641A (en) | 1988-08-15 | 1994-12-27 | American Maize Technology, Inc. | Method for making a steroid water soluble |
| US5134127A (en) | 1990-01-23 | 1992-07-28 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5543157A (en) | 1990-03-06 | 1996-08-06 | The Procter & Gamble Company | Solid consumer product compositions containing small particle clyclodextrin complexes |
| US5382434A (en) | 1991-03-12 | 1995-01-17 | Akzo N.V. | Low steroid dose dry pharmaceutical preparation |
| US5928668A (en) | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
| US5976570A (en) | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
| US6156341A (en) | 1994-07-04 | 2000-12-05 | Schering Aktiensgesellschaft | Low-dosed steroid tablets that contain gallic acid ester as an antioxidant, process for production, and use |
| US5798338A (en) | 1994-07-20 | 1998-08-25 | Schering Aktiengesellschaft | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
| US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| DE19916383A1 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition with an extrusion |
| US6958326B2 (en) | 2000-12-20 | 2005-10-25 | Schering Ag | Cyclodextrin-drospirenone inclusion complexes |
| US7163931B2 (en) | 2000-12-20 | 2007-01-16 | Schering Aktiengesellchaft | Compositions of estrogen-cyclodextrin complexes |
| US7569557B2 (en) | 2000-12-20 | 2009-08-04 | Bayer Schering Pharma Ag | Compositions of estrogen-cyclodextrin complexes |
| US20050020554A1 (en) | 2003-06-06 | 2005-01-27 | Ahmed Salah U. | Stability of hormone formulations |
| US20050207990A1 (en) | 2004-03-10 | 2005-09-22 | Adrian Funke | Stabilised supersaturated solids of lipophilic drugs |
| US20050220825A1 (en) | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
| US20080175905A1 (en) | 2006-11-29 | 2008-07-24 | Wyeth | Estrogen/serm and estrogen/progestin bi-layer tablets |
| US20090117183A1 (en) | 2007-11-05 | 2009-05-07 | Sabine Fricke | Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same |
Cited By (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9248136B2 (en) | 2011-11-23 | 2016-02-02 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8993548B2 (en) | 2011-11-23 | 2015-03-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8993549B2 (en) | 2011-11-23 | 2015-03-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9114145B2 (en) | 2011-11-23 | 2015-08-25 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9114146B2 (en) | 2011-11-23 | 2015-08-25 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10639375B2 (en) | 2012-06-18 | 2020-05-05 | Therapeuticsmd, Inc. | Progesterone formulations |
| US9012434B2 (en) | 2012-06-18 | 2015-04-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
| US11865179B2 (en) | 2012-06-18 | 2024-01-09 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
| US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9006222B2 (en) | 2012-06-18 | 2015-04-14 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11033626B2 (en) | 2012-06-18 | 2021-06-15 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
| US8987238B2 (en) | 2012-06-18 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
| US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10398708B2 (en) | 2014-10-22 | 2019-09-03 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10668082B2 (en) | 2014-10-22 | 2020-06-02 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN106692097A (en) * | 2015-07-16 | 2017-05-24 | 北京万生药业有限责任公司 | Reduced glutathione medicinal preparation |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10912783B2 (en) | 2015-07-23 | 2021-02-09 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10532059B2 (en) | 2016-04-01 | 2020-01-14 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| JP2022501472A (en) * | 2018-09-19 | 2022-01-06 | アイエスピー インヴェストメンツ エルエルシー | Peroxide-stable polymer composition, its manufacturing method, and its use |
| JP7459068B2 (en) | 2018-09-19 | 2024-04-01 | アイエスピー インヴェストメンツ エルエルシー | Peroxide-stable polymer compositions and methods of production thereof, and uses thereof |
| JP2020193229A (en) * | 2019-02-13 | 2020-12-03 | 富士製薬工業株式会社 | Oral solid composition, production method thereof, and oral tablet obtained by the production method |
| CN115813937A (en) * | 2022-12-01 | 2023-03-21 | 南通联亚药业股份有限公司 | A stable pharmaceutical composition containing drospirenone and estradiol and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012120365A1 (en) | Stable pharmaceutical composition comprising ethinyl estradiol | |
| EP2040683B2 (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| US8617597B2 (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| AU2004275470B2 (en) | Improved stability of progestogen formulations | |
| EP3701944B1 (en) | Orodispersible dosage unit containing an estetrol component | |
| HUP0302499A2 (en) | Pharmaceutical compositions of estrogen-cyclodextrin complexes and process for their preparation | |
| MX2008000844A (en) | Oral contraception with trimegestone. | |
| JPH07196513A (en) | Medicinal granule | |
| CN107812195B (en) | Stable pharmaceutical composition of (6S) -5-methyl-tetrahydrofolate calcium salt | |
| US20160045440A1 (en) | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | |
| WO2014125352A1 (en) | Pharmaceutical compositions comprising tadalafil | |
| EP3256105B1 (en) | Method of producing a granulated composition | |
| AU2013202756B2 (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| AU2017260799B2 (en) | Use of sugar-alcohols in tibolone compositions | |
| HK1179165A (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| HK1131917B (en) | Pharmaceutical composition containing a tetrahydrofolic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12715426 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12715426 Country of ref document: EP Kind code of ref document: A1 |